Study Summary
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.
Want to learn more about this trial?
Request More InfoInterventions
CD371-specific/YSNVz/I-18 CAR T cellsBIOLOGICAL
Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | United States |
| Memorial Sloan Kettering Monmouth (Limited protocol activities) | Middletown | New Jersey | United States |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | United States |
| Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) | Commack | New York | United States |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | United States |
| Memorial Sloan Kettering Cancer Center (All protocol activites) | New York | New York | United States |
| Memorial Sloan Kettering Nassau (Limited Protocol Activites) | Rockville Centre | New York | United States |